These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36200096)

  • 41. Population pharmacokinetic modeling of pyrotinib in patients with HER2-positive advanced or metastatic breast cancer.
    Wen HN; Liu YX; Xu D; Zhao KJ; Jiao Z
    Eur J Pharm Sci; 2021 Apr; 159():105729. PubMed ID: 33484815
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2).
    Yang G; Xu H; Yang Y; Zhang S; Xu F; Hao X; Li J; Xing P; Hu X; Liu Y; Wang L; Lin L; Wang Z; Duan J; Wang J; Wang Y
    BMC Med; 2022 Aug; 20(1):277. PubMed ID: 36031613
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Metastatic Cervical Adenocarcinoma Patient Carrying
    Liu J; Zhuo Y; Wang F; Li Z; Lin Y; Li L; Pan J; Song Y; Du H; Li C; Xu Q
    Onco Targets Ther; 2021; 14():4833-4836. PubMed ID: 34556997
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Apatinib exhibits synergistic effect with pyrotinib and reverses acquired pyrotinib resistance in HER2-positive gastric cancer via stem cell factor/c-kit signaling and its downstream pathways.
    Su B; Huang T; Jin Y; Yin H; Qiu H; Yuan X
    Gastric Cancer; 2021 Mar; 24(2):352-367. PubMed ID: 33030616
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis.
    Chen Q; Ouyang D; Anwar M; Xie N; Wang S; Fan P; Qian L; Chen G; Zhou E; Guo L; Gu X; Ding B; Yang X; Liu L; Deng C; Xiao Z; Li J; Wang Y; Zeng S; Hu J; Zhou W; Qiu B; Wang Z; Weng J; Liu M; Li Y; Tang T; Wang J; Zhang H; Dai B; Tang W; Wu T; Xiao M; Li X; Liu H; Li L; Yi W; Ouyang Q
    Front Oncol; 2020; 10():811. PubMed ID: 32528890
    [No Abstract]   [Full Text] [Related]  

  • 46. HER2-amplified metastatic lung adenocarcinoma responds to fourth-line pyrotinib therapy: A case report.
    Gong K; Yang Y; Huang H; Kuang X; Yang X
    Mol Clin Oncol; 2021 Oct; 15(4):213. PubMed ID: 34476097
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pyrotinib and chrysin synergistically potentiate autophagy in HER2-positive breast cancer.
    Liu X; Zhang X; Shao Z; Zhong X; Ding X; Wu L; Chen J; He P; Cheng Y; Zhu K; Zheng D; Jing J; Luo T
    Signal Transduct Target Ther; 2023 Dec; 8(1):463. PubMed ID: 38110365
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.
    Xu B; Yan M; Ma F; Hu X; Feng J; Ouyang Q; Tong Z; Li H; Zhang Q; Sun T; Wang X; Yin Y; Cheng Y; Li W; Gu Y; Chen Q; Liu J; Cheng J; Geng C; Qin S; Wang S; Lu J; Shen K; Liu Q; Wang X; Wang H; Luo T; Yang J; Wu Y; Yu Z; Zhu X; Chen C; Zou J;
    Lancet Oncol; 2021 Mar; 22(3):351-360. PubMed ID: 33581774
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study.
    Ouyang DJ; Chen QT; Anwar M; Xie N; Ouyang QC; Fan PZ; Qian LY; Chen GN; Zhou EX; Guo L; Gu XW; Ding BN; Yang XH; Liu LP; Deng C; Xiao Z; Li J; Wang YQ; Zeng S; Wang S; Yi W
    Front Pharmacol; 2021; 12():682568. PubMed ID: 34512325
    [No Abstract]   [Full Text] [Related]  

  • 50. Long term survival achieved through combination of almonertinib and pyrotinib in EGFR-mutant/HER2-amplified advanced NSCLC patient: a case report and literature review.
    Pan X; Zhou X
    Front Oncol; 2024; 14():1397238. PubMed ID: 39184039
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pyrotinib-associated acute kidney injury: A case report.
    Miao K; Zhang L; Si X
    Cancer Innov; 2022 Dec; 1(4):344-347. PubMed ID: 38089087
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma.
    González-Alonso P; Chamizo C; Moreno V; Madoz-Gúrpide J; Carvajal N; Daoud L; Zazo S; Martín-Aparicio E; Cristóbal I; Rincón R; García-Foncillas J; Rojo F
    Int J Mol Sci; 2015 Aug; 16(8):19447-57. PubMed ID: 26287187
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dalpiciclib Combined With Pyrotinib and Letrozole in Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer (LORDSHIPS): A Phase Ib Study.
    Zhang J; Meng Y; Wang B; Wang L; Cao J; Tao Z; Li T; Yao W; Hu X
    Front Oncol; 2022; 12():775081. PubMed ID: 35321427
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with non-small-cell lung cancer and ERBB2 mutation.
    Wu Y; Ni J; Chang X; Zhang X; Zhang L
    Thorac Cancer; 2020 Jul; 11(7):2051-2055. PubMed ID: 32458584
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pathological Complete Response from Pyrotinib Combined with Trastuzumab, Paclitaxel and Cisplatin in a Postpartum Woman with HER2-Positive Locally Advanced Breast Cancer: A Case Report.
    He L; Zhang F; Ma Y; Zuo L; Xu Y
    Onco Targets Ther; 2020; 13():8749-8756. PubMed ID: 32943881
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib.
    Zhang X; Lv J; Wu Y; Qin N; Ma L; Li X; Nong J; Zhang H; Zhang Q; Yang X; Shi H; Wang J; Zhang S
    Front Oncol; 2020; 10():1162. PubMed ID: 32850330
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer.
    Wang Y; Yuan X; Li J; Liu Z; Li X; Wang Z; Wei L; Li Y; Wang X
    Front Cell Dev Biol; 2021; 9():785796. PubMed ID: 34977029
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness and safety of pyrotinib-based therapy in patients with HER2-positive metastatic breast cancer: A real-world retrospective study.
    Li C; Bian X; Liu Z; Wang X; Song X; Zhao W; Liu Y; Yu Z
    Cancer Med; 2021 Dec; 10(23):8352-8364. PubMed ID: 34672424
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Potential mechanism of pyrotinib-induced diarrhea was explored by gut microbiome and ileum metabolomics.
    Lai J; Zhuo X; Yin K; Jiang F; Liu L; Xu X; Liu H; Wang J; Zhao J; Xu W; Yang S; Guo H; Yuan X; Lin X; Qi F; Fu G
    Anticancer Drugs; 2023 Jul; 34(6):747-762. PubMed ID: 36378136
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neoadjuvant pyrotinib plus trastuzumab and nab-paclitaxel for HER2-positive early or locally advanced breast cancer: an exploratory phase II trial.
    Zhong X; He P; Chen J; Yan X; Wei B; Zhang Z; Bu H; Li J; Tian T; Lv Q; Wang X; Li H; Wang J; Huang J; Suo J; Liu X; Zheng H; Luo T
    Gland Surg; 2022 Jan; 11(1):216-225. PubMed ID: 35242683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.